As the ROS1 protein is deregulated in a wide range of tumors other than NSCLC, including brain [110,111,112,113], breast [26], liver [114], colon [115], stomach [116], ovarian [117] and oral carcinomas [25], and chronic myelomonocytic leukemia [118], the development of ROS1 electrovaccination may also provide a new therapeutic option for patients affected by these ROS1-expressing cancers. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.